🇺🇸 FDA
Patent

US 11534453

RNAi therapy for hepatitis B virus infection

granted A61KA61K31/713A61K38/16

Quick answer

US patent 11534453 (RNAi therapy for hepatitis B virus infection) held by Arrowhead Pharmaceuticals, Inc. expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/713, A61K38/16, A61K47/549, A61K47/554